JAK2 activation by growth hormone and other cytokines

scientific article

JAK2 activation by growth hormone and other cytokines is …
instance of (P31):
scholarly articleQ13442814
review articleQ7318358

External links are
P356DOI10.1042/BJ20141293
P932PMC publication ID4325515
P698PubMed publication ID25656053
P5875ResearchGate publication ID272078782

P50authorAndrew J. BrooksQ55155147
P2093author name stringMichael J Waters
P2860cites workStimulation of c-Src by prolactin is independent of Jak2.Q42928957
Prediction of the structure of human Janus kinase 2 (JAK2) comprising the two carboxy-terminal domains reveals a mechanism for autoregulationQ43565424
Dimerization and signal transduction of the growth hormone receptorQ44308491
Src mediates prolactin-dependent proliferation of T47D and MCF7 cells via the activation of focal adhesion kinase/Erk1/2 and phosphatidylinositol 3-kinase pathwaysQ44542433
Turning the growth hormone receptor on: evidence that hormone binding induces subunit rotationQ45067684
An agonist-induced conformational change in the growth hormone receptor determines the choice of signalling pathway.Q46589328
The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitorQ46713383
The Asn505 mutation of the c-MPL gene, which causes familial essential thrombocythemia, induces autonomous homodimerization of the c-Mpl protein due to strong amino acid polarityQ47686615
Ligand-independent dimerization of the human prolactin receptor isoforms: functional implicationsQ50335953
Efficiency of signalling through cytokine receptors depends critically on receptor orientationQ22003959
Hexameric structure and assembly of the interleukin-6/IL-6 alpha-receptor/gp130 complexQ24306425
Human growth hormone and extracellular domain of its receptor: crystal structure of the complexQ24308045
Differential activation of acute phase response factor/STAT3 and STAT1 via the cytoplasmic domain of the interleukin 6 signal transducer gp130. I. Definition of a novel phosphotyrosine motif mediating STAT1 activationQ24319880
The structure of the GM-CSF receptor complex reveals a distinct mode of cytokine receptor activationQ24322589
Growth hormone receptor and serum binding protein: purification, cloning and expressionQ24339632
JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosisQ24609999
Crystal Structure of an Affinity-matured Prolactin Complexed to Its Dimerized Receptor Reveals the Topology of Hormone Binding Site 2Q27646645
An unusual cytokine:Ig-domain interaction revealed in the crystal structure of leukemia inhibitory factor (LIF) in complex with the LIF receptorQ27646869
Structural Organization of a Full-Length gp130/LIF-R Cytokine Receptor Transmembrane ComplexQ27652013
Structural Characterization of the Stem–Stem Dimerization Interface between Prolactin Receptor Chains Complexed with the Natural HormoneQ27664687
Crystal structures of the JAK2 pseudokinase domain and the pathogenic mutant V617FQ27670859
Structure of the pseudokinase-kinase domains from protein kinase TYK2 reveals a mechanism for Janus kinase (JAK) autoinhibitionQ27683852
Dual mechanism of interleukin-3 receptor blockade by an anti-cancer antibodyQ27694580
Activation of GH signaling and GH-independent stimulation of growth in zebrafish by introduction of a constitutively activated GHR construct.Q51621525
gp130 activation is regulated by D2-D3 interdomain connectivity.Q52633085
Open-label study of oral CEP-701 (lestaurtinib) in patients with polycythaemia vera or essential thrombocythaemia with JAK2-V617F mutation.Q54346714
Regulation of JAK2 activation by Janus homology 2: evidence from molecular dynamics simulations.Q54479910
Dimerisation of the glycophorin A transmembrane segment in membranes probed with the ToxR transcription activator.Q54577274
Control of growth hormone (GH) binding protein release from human hepatoma cells expressing full-length GH receptorQ56936497
Role of the growth hormone–IGF-1 axis in cancerQ57252658
Ligand-independent oligomerization of cell-surface erythropoietin receptor is mediated by the transmembrane domainQ64008501
Interaction of the growth hormone receptor cytoplasmic domain with the JAK2 tyrosine kinaseQ72796301
The role of receptor dimerization domain residues in growth hormone signalingQ73067623
Binding and functional studies with the growth hormone receptor antagonist, B2036-PEG (pegvisomant), reveal effects of pegylation and evidence that it binds to a receptor dimerQ73739058
General classes and functions of four-helix bundle cytokinesQ77903163
The duplicitous nature of the Lyn tyrosine kinase in growth factor signalingQ79791774
Signaling conformations of the tall cytokine receptor gp130 when in complex with IL-6 and IL-6 receptorQ81749177
Activity of therapeutic JAK 1/2 blockade in graft-versus-host diseaseQ87635679
The role of pacritinib in the management of myelofibrosisQ87710103
Tofacitinib versus methotrexate in rheumatoid arthritisQ88103514
Functional mimicry of a protein hormone by a peptide agonist: the EPO receptor complex at 2.8 AQ27732820
Crystallographic evidence for preformed dimers of erythropoietin receptor before ligand activationQ27766884
Lyn physically associates with the erythropoietin receptor and may play a role in activation of the Stat5 pathwayQ28269830
The growth hormone receptor: mechanism of activation and clinical implicationsQ28289018
Dimerization of the extracellular domain of the human growth hormone receptor by a single hormone moleculeQ28609946
Differential activation of acute phase response factor/Stat3 and Stat1 via the cytoplasmic domain of the interleukin 6 signal transducer gp130. II. Src homology SH2 domains define the specificity of stat factor activationQ28637692
Structural design and molecular evolution of a cytokine receptor superfamilyQ29618154
Alternative modes of GM-CSF receptor activation revealed using activated mutants of the common beta-subunit.Q30156952
Effects of clinically relevant MPL mutations in the transmembrane domain revealed at the atomic level through computational modelingQ30406240
Molecular basis for pseudokinase-dependent autoinhibition of JAK2 tyrosine kinaseQ30658298
Epitope map for a growth hormone receptor agonist monoclonal antibody, MAb 263.Q31153125
Self assembly of the transmembrane domain promotes signal transduction through the erythropoietin receptorQ32079971
Active conformation of the erythropoietin receptor: random and cysteine-scanning mutagenesis of the extracellular juxtamembrane and transmembrane domainsQ33231718
gp130 dimerization in the absence of ligand: preformed cytokine receptor complexesQ33246799
Evolution of Class I cytokine receptorsQ33291265
F104S c-Mpl responds to a transmembrane domain-binding thrombopoietin receptor agonist: proof of concept that selected receptor mutations in congenital amegakaryocytic thrombocytopenia can be stimulated with alternative thrombopoietic agentsQ33388407
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosisQ33399980
Construction and genetic selection of small transmembrane proteins that activate the human erythropoietin receptor.Q33530296
Binding in the growth hormone receptor complexQ33593803
Mechanistic insights into activation and SOCS3-mediated inhibition of myeloproliferative neoplasm-associated JAK2 mutants from biochemical and structural analysesQ33857008
CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia.Q33909621
The molecular regulation of Janus kinase (JAK) activationQ33956113
Crystal structure of the entire ectodomain of gp130: insights into the molecular assembly of the tall cytokine receptor complexesQ33967437
Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformationQ34245259
The JAK/STAT signaling pathwayQ34305849
gp130 at the nexus of inflammation, autoimmunity, and cancerQ34378756
Mechanism of activation of protein kinase JAK2 by the growth hormone receptorQ34420222
Dynamic analysis of GH receptor conformational changes by split luciferase complementationQ34422493
Ab initio modeling and experimental assessment of Janus Kinase 2 (JAK2) kinase-pseudokinase complex structureQ34671755
Forced dimerization of gp130 leads to constitutive STAT3 activation, cytokine-independent growth, and blockade of differentiation of embryonic stem cellsQ34698039
Growth hormone signaling in human T47D breast cancer cells: potential role for a growth hormone receptor-prolactin receptor complexQ34712091
MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasiaQ34770384
MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort.Q34775393
Thrombopoietin receptor activation: transmembrane helix dimerization, rotation, and allosteric modulationQ35043880
Mutations in the transmembrane and juxtamembrane domains enhance IL27R transforming activityQ35134457
Signal transduction mediated by growth hormone receptor and its chimeric molecules with the granulocyte colony-stimulating factor receptorQ36031581
Jak2 FERM domain interaction with the erythropoietin receptor regulates Jak2 kinase activityQ36483460
Cytokine receptor signaling through the Jak-Stat-Socs pathway in disease.Q36701486
Comprehensive review of JAK inhibitors in myeloproliferative neoplasms.Q36776428
JAK2, but not Src family kinases, is required for STAT, ERK, and Akt signaling in response to growth hormone in preadipocytes and hepatoma cellsQ36826553
Role of JAK2 in the pathogenesis and therapy of myeloproliferative disordersQ36919975
A sequential dimerization mechanism for erythropoietin receptor activationQ37353234
Improved targeting of JAK2 leads to increased therapeutic efficacy in myeloproliferative neoplasmsQ37670068
Inhibition of IL-6 family cytokines by SOCS3.Q37676036
Perspectives for the use of structural information and chemical genetics to develop inhibitors of Janus kinasesQ37687519
Prolactin regulation of the prostate gland: a female player in a male gameQ37942413
Lymphoid malignancies: Another face to the Janus kinases.Q38075971
Signalling by the βc family of cytokinesQ38093731
Granulocyte colony-stimulating factor receptor mutations in myeloid malignancyQ38211431
Who climbs the tryptophan ladder? On the structure and function of the WSXWS motif in cytokine receptors and thrombospondin repeatsQ38214919
A new mechanism for growth hormone receptor activation of JAK2, and implications for related cytokine receptorsQ38237652
Profile of pacritinib and its potential in the treatment of hematologic disordersQ38244524
Selective JAK inhibitorsQ38261371
Growth hormone (GH)-independent dimerization of GH receptor by a leucine zipper results in constitutive activationQ38311941
An activating mutation in the transmembrane domain of the granulocyte colony-stimulating factor receptor in patients with acute myeloid leukemiaQ38363447
Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapyQ38824881
Lyn kinase plays important roles in erythroid expansion, maturation and erythropoietin receptor signalling by regulating inhibitory signalling pathways that control survival.Q39022552
Two domains of the erythropoietin receptor are sufficient for Jak2 binding/activation and functionQ39126733
Orientation-specific signalling by thrombopoietin receptor dimers.Q39592020
Autoinhibition of Jak2 tyrosine kinase is dependent on specific regions in its pseudokinase domainQ39745564
The influence of domain structures on the signal transduction of chimeric receptors derived from the erythropoietin receptor.Q39893198
Dimerization by a cytokine receptor is necessary for constitutive activation of JAK2V617F.Q40031223
Role of the growth hormone (GH) receptor transmembrane domain in receptor predimerization and GH-induced activationQ40141599
An amphipathic motif at the transmembrane-cytoplasmic junction prevents autonomous activation of the thrombopoietin receptor.Q40357987
Model for growth hormone receptor activation based on subunit rotation within a receptor dimerQ40382202
Active and inactive orientations of the transmembrane and cytosolic domains of the erythropoietin receptor dimerQ40613603
The interface between self-assembling erythropoietin receptor transmembrane segments corresponds to a membrane-spanning leucine zipperQ40619204
Association of Lyn tyrosine kinase to the GM-CSF and IL-3 receptor common betac subunit and role of Src tyrosine kinases in DNA synthesis and anti-apoptosisQ40900402
Disulfide linkage of growth hormone (GH) receptors (GHR) reflects GH-induced GHR dimerization. Association of JAK2 with the GHR is enhanced by receptor dimerizationQ40919215
The mapping of the Lyn kinase binding site of the common beta subunit of IL-3/granulocyte-macrophage colony-stimulating factor/IL-5 receptorQ40974112
Activation of chimeric and full-length growth hormone receptors by growth hormone receptor monoclonal antibodies. A specific conformational change may be required for full-length receptor signaling.Q41056199
Signal transduction of interleukin-6 involves tyrosine phosphorylation of multiple cytosolic proteins and activation of Src-family kinases Fyn, Hck, and Lyn in multiple myeloma cell linesQ41075836
Functional replacement of cytokine receptor extracellular domains by leucine zippersQ41149871
The box1 domain of the erythropoietin receptor specifies Janus kinase 2 activation and functions mitogenically within an interleukin 2 beta-receptor chimeraQ41185142
JAK2 is essential for activation of c-fos and c-myc promoters and cell proliferation through the human granulocyte-macrophage colony-stimulating factor receptor in BA/F3 cells.Q41197797
Proline-rich sequence-mediated Jak2 association to the prolactin receptor is required but not sufficient for signal transductionQ41347075
Rational design of potent antagonists to the human growth hormone receptorQ41618965
Structural snapshots of full-length Jak1, a transmembrane gp130/IL-6/IL-6Rα cytokine receptor complex, and the receptor-Jak1 holocomplexQ41792413
P275copyright licenseCreative Commons Attribution 3.0 UnportedQ14947546
P6216copyright statuscopyrightedQ50423863
P433issue1
P407language of work or nameEnglishQ1860
P921main subjectmembrane proteinQ423042
peptideQ172847
cytokineQ212354
enzymeQ8047
cell surface receptorQ2476074
hormoneQ11364
proto-oncogene proteinQ66020913
neoplasm proteinQ66894191
P1104number of pages11
P304page(s)1-11
P577publication date2015-02-15
P1433published inBiochemical JournalQ864221
P1476titleJAK2 activation by growth hormone and other cytokines
P478volume466

Reverse relations

cites work (P2860)
Q52655332Application of a Genetic Risk Score to Racially Diverse Type 1 Diabetes Populations Demonstrates the Need for Diversity in Risk-Modeling.
Q36344846Binding of interferon reduces the force of unfolding for interferon receptor 1.
Q92063512Combination therapy with ropivacaine-loaded liposomes and nutrient deprivation for simultaneous cancer therapy and cancer pain relief
Q57252653Cytokine Receptors
Q91960810Deficiency in BDNF/TrkB Neurotrophic Activity Stimulates δ-Secretase by Upregulating C/EBPβ in Alzheimer's Disease
Q38758497Defining human insulin-like growth factor I gene regulation
Q46241287Diversification of the insulin-like growth factor 1 gene in mammals
Q58555152Expression of the growth hormone receptor isoforms and its correlation with the metabolic profile in morbidly obese subjects
Q40798911Fos-Zippered GH Receptor Cytosolic Tails Act as Jak2 Substrates and Signal Transducers
Q90230800Growth Hormone Upregulates Melanocyte-Inducing Transcription Factor Expression and Activity via JAK2-STAT5 and SRC Signaling in GH Receptor-Positive Human Melanoma
Q52652594Growth hormone - past, present and future.
Q42207921Growth hormone and insulin-like growth factor 1 affect the severity of Graves' disease
Q52313979Growth hormone receptor-deficient pigs resemble the pathophysiology of human Laron syndrome and reveal altered activation of signaling cascades in the liver.
Q38671410Hepatic JAK2 protects against atherosclerosis through circulating IGF-1.
Q38570383Immunological Consequences of JAK Inhibition: Friend or Foe?
Q54114182Insulinlike Growth Factor 1 Gene Variation in Vertebrates.
Q38781485Internalization and synaptogenic effect of GH in retinal ganglion cells (RGCs).
Q45818945Isogenic Cellular Systems Model the Impact of Genetic Risk Variants in the Pathogenesis of Type 1 Diabetes
Q26782539JAK kinase targeting in hematologic malignancies: a sinuous pathway from identification of genetic alterations towards clinical indications
Q92617002JAK2/STAT3 is associated with the inflammatory process in periapical granuloma
Q38695289Macrophage JAK2 deficiency protects against high-fat diet-induced inflammation.
Q33884280Molecular interactions of EphA4, growth hormone receptor, Janus kinase 2, and signal transducer and activator of transcription 5B.
Q92857474Molecular mechanisms underlying the actions of arachidonic acid-derived prostaglandins on peripheral nociception
Q89828211Molecular structure and function of Janus kinases: implications for the development of inhibitors
Q41196669Nectin-like molecule-4/cell adhesion molecule 4 inhibits the ligand-induced dimerization of ErbB3 with ErbB2.
Q44159046Network-Based Method for Identifying Co- Regeneration Genes in Bone, Dentin, Nerve and Vessel Tissues.
Q50516807Neuroprotection by GH against excitotoxic-induced cell death in retinal ganglion cells.
Q42039904Potential humoral mediators of remote ischemic preconditioning in patients undergoing surgical coronary revascularization
Q56531947Receptor-mediated dimerization of JAK2 FERM domains is required for JAK2 activation
Q90165530Regulation of gene expression by growth hormone
Q98771847Structural Perspectives on Extracellular Recognition and Conformational Changes of Several Type-I Transmembrane Receptors
Q61797690Targeting growth hormone function: strategies and therapeutic applications
Q42801147The 20kDa and 22kDa forms of human growth hormone (hGH) exhibit different intracellular signalling profiles and properties
Q51766789The Growth Hormone Receptor: Mechanism of Receptor Activation, Cell Signaling, and Physiological Aspects.
Q38789207The New Genomics: What Molecular Databases Can Tell us About Human Population Variation and Endocrine Disease
Q94555032The effects of growth hormone on therapy resistance in cancer
Q92071391There and Back Again: A Cytokine Receptor's Tail
Q26739716Ubc13: the Lys63 ubiquitin chain building machine
Q28817460Zinc deficiency affects the STAT1/3 signaling pathways in part through redox-mediated mechanisms

Search more.